The Prognostic Subgroups as Defined by the Patterns of Epstein-Barr Virus Infection in Patients with Hodgkin Lymphoma
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background : The purpose of this study was to investigate the prognostic significance of the Epstein-Barr virus (EBV) infected non-neoplastic lymphocytes in patients with Hodgkin lymphoma (HL). Methods : Seventy-seven cases of HL were evaluated by immunohistochemical analysis and EBV-encoded RNA in situ hybridization. The cases were divided into three groups according to the EBV status. EBV was negative in 48 cases (group 1), EBV was located in the Hodgkin/Reed-Sternberg (HRS) cells, but not in the non-neoplastic lymphocytes in 20 cases (26%) (group 2) and EBV was located in both the HRS cells and the non-neoplastic lymphocytes in 9 cases (12%) (group 3). Results : The groups differed with respect to the age distribution, the clinical presentation and the prognosis. The median ages were 30 (group 1), 47.5 (group 2) and 23 years (group 3) (p = 0.011). B symptoms (p = 0.007) and the histologic subtype of mixed cellularity classical HL (p = 0.001) were more common in the EBV-positive patients than in their EBV-negative counterparts. Two patients from group 3 had associated chronic EBV infection syndrome. The five-year survival rate was 97.56% in group 1, 75.76% in group 2 and 100% in group 3 (p = 0.0178). Conclusions : HL with EBV located in both the HRS cells and the non-neoplastic lymphocytes is a distinct prognostic subgroup that has better survival than the HL with EBV located in only the HRS cells.
Abstract
Background : The purpose of this study was to investigate the prognostic significance of the Epstein-Barr virus (EBV) infected non-neoplastic lymphocytes in patients with Hodgkin lymphoma (HL). Methods : Seventy-seven cases of HL were evaluated by immunohistochemical analysis and EBV-encoded RNA in situ hybridization. The cases were divided into three groups according to the EBV status. EBV was negative in 48 cases (group 1), EBV was located in the Hodgkin/Reed-Sternberg (HRS) cells, but not in the non-neoplastic lymphocytes in 20 cases (26%) (group 2) and EBV was located in both the HRS cells and the non-neoplastic lymphocytes in 9 cases (12%) (group 3). Results : The groups differed with respect to the age distribution, the clinical presentation and the prognosis. The median ages were 30 (group 1), 47.5 (group 2) and 23 years (group 3) (p = 0.011). B symptoms (p = 0.007) and the histologic subtype of mixed cellularity classical HL (p = 0.001) were more common in the EBV-positive patients than in their EBV-negative counterparts. Two patients from group 3 had associated chronic EBV infection syndrome. The five-year survival rate was 97.56% in group 1, 75.76% in group 2 and 100% in group 3 (p = 0.0178). Conclusions : HL with EBV located in both the HRS cells and the non-neoplastic lymphocytes is a distinct prognostic subgroup that has better survival than the HL with EBV located in only the HRS cells.
참고문헌 (30)
- Epstein MA, "Virus particles in cultured lymphoblasts from Burkitt’s lymphoma", Lancet, 1, pp.702~703 (1964)
- Henle G, "Relation of Burkitt’s tumor-associated herpes-ytpe virus to infectious mononucleosis", Proc Natl Acad Sci U S A, 59, pp.94~101 (1968)
- Siemer D, "EBV transformation overrides gene expression patterns of B cell differentiation stages", Mol Immunol, 45, pp.3133~3141 (2008)
- Young LS, "Epstein-Barr virus and oncogenesis:from latent genes to tumours", Oncogene, 22, pp.5108~5121 (2003)
- Nishikori M, "Molecular pathogenesis of Hodgkin lymphoma", Int J Hematol, 83, pp.398~403 (2006)
- Evans AS, "A population-based case-control study of EBV and other viral antibodies among persons with Hodgkin’s disease and their siblings", Int J Cancer, 34, pp.149~157 (1984)
- Pallesen G, "Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin’s disease", Lancet, 337, pp.320~322 (1991)
- Thorley-Lawson DA, "Epstein-Barr virus:exploiting the immune system", Nat Rev Immunol, 1, pp.75~82 (2001)
- Vestlev PM, "Prognosis of Hodgkin’s disease is not influenced by Epstein-Barr virus latent membrane protein", Int J Cancer, 50, pp.670~671 (1992)
- Enblad G, "Lack of correlation between EBV serology and presence of EBV in the Hodgkin and Reed-Sternberg cells of patients with Hodgkin’s disease", Int J Cancer, 72, pp.394~397 (1997)
- Vassallo J, ""Expression of Epstein-Barr virus in classical Hodgkin’s lymphomas in Brazilian adult patients", Haematologica, 86, pp.1227~1228 (2001)
- Morente MM, "Adverse clinical outcome in Hodgkin’s disease is associated with loss of retinoblastoma protein expression,high Ki67 proliferation index,and absence of Epstein-Barr virus-latent membrane protein 1 expression", Blood, 90, pp.2429~2436 (1997)
- Axdorph U, "Epstein-Barr virus expression in Hodgkin’s disease in relation to patient characteristics,serum factors and blood lymphocyte function", Br J Cancer, 81, pp.1182~1187 (1999)
- Naresh KN, "Epstein-Barr virus association in classical Hodgkin’s disease provides survival advantage to patients and correlates with higher expression of proliferation markers in Reed-Sternberg cells", Ann Oncol, 11, pp.91~96 (2000)
- Enblad G, "Epstein-Barr virus distribution in Hodgkin’s disease in an unselected Swedish population", Acta Oncol, 38, pp.425~429 (1999)
- Kwon JM, "The effect of Epstein-Barr virus status on clinical outcome in Hodgkin’s lymphoma", Ann Hematol, 85, pp.463~468 (2006)
- Keegan TH, "Epstein-Barr virus as a marker of survival after Hodgkin’s lymphoma:a population-based study", J Clin Oncol, 23, pp.7604~7613 (2005)
- Khan G, "Presence of Epstein-Barr virus in Hodgkin’s disease is not exclusive to Reed-Sternberg cells", Am J Pathol, 140, pp.757~762 (1992)
- Faumont N, "In Hodgkin’s disease Reed-Sternberg cells and normal B-lymphocytes are infected by related Epstein-Barr virus strains", Virus Res, 101, pp.163~173 (2004)
- Garcia-Cosio M, "Analysis of Epstein-Barr virus strains and variants in classical Hodgkin’s lymphoma by laser microdissection", Histol Histopathol, 23, pp.209~217 (2008)
- Kenney JL, "Antisense to the epsteinbarr virus(EBV)-encoded latent membrane protein 1(LMP-1)suppresses LMP-1 and bcl-2 expression and promotes apoptosis in EBVimmortalized B cells", Blood, 92, pp.1721~1727 (1998)
- Katebi M, ""Frequency of Epstein-Barr virus expression in various histological subtypes of Hodgkin’s lymphoma", Histopathology, 52, pp.775~777 (2008)
- Luftig M, "Epstein-Barr virus latent infection membrane protein 1 TRAF-binding site induces NIK", IKK alphadependent noncanonical NF-kappaB activation, 2004, pp.101, 141~146
- Krappmann D, "Molecular mechanisms of constitutive NF-kappaB", Rel activation in Hodgkin, Oncogene, pp.1999, 18[DOI]
- Uccini S, "High frequency of Epstein-Barr virus genome detection in Hodgkin’s disease of HIV-positive patients", Int J Cancer, 46, pp.581~585 (1990)
- Kapatai G, "Contribution of the Epstein Barr virus to the molecular pathogenesis of Hodgkin lymphoma", J Clin Pathol, 60, pp.1342~1349 (2007)
- Armstrong AA, "Epstein-Barr virus and Hodgkin’s disease:further evidence for the three disease hypothesis", Leukemia, 12, pp.1272~1276 (1998)
- Glaser SL, "Epstein-Barr virus-associated Hodgkin’s disease:epidemiologic characteristics in international data", Int J Cancer, 70, pp.375~382 (1997)
- Jarrett RF, "Detection of Epstein-Barr virus genomes in Hodgkin’s disease:relation to age", J Clin Pathol, 44, pp.844~848 (1991)
- Asada H, "Hypersensitivity to mosquito bites:a unique pathogenic mechanism linking Epstein-Barr virus infection,allergy and oncogenesis", J Dermatol Sci, 45, pp.153~160 (2007)